Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

19.92 +1.27 (+6.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
Via Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
Via Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via GlobeNewswire
Recap: MediWound Q2 Earnings
  MediWound (NASDAQ:MDWD) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial
Via Benzinga
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
From MediWound Ltd.
Via GlobeNewswire
MediWound's EscharEx Shows Safe, Effective, Rapid Debridement Of Leg Ulcers
Via Benzinga
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. 
Via Benzinga
MediWound to Report Third Quarter 2022 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
MediWound: Q1 Earnings Insights
MediWound (NASDAQ:MDWD) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
MediWound Announces Formation of Strategic Advisory Board
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities 
From MediWound Ltd.
Via GlobeNewswire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted 
From MediWound Ltd.
Via GlobeNewswire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
Gross Proceeds of $30.5 Million Raised 
From MediWound Ltd.
Via GlobeNewswire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Dow Turns Higher; Crude Oil Rises 0.7%
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday. 
Via Benzinga
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers 
Via Benzinga
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 17, 2022
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter. 
Via Benzinga
Preview: MediWound's Earnings
MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that MediWound will... 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
MediWound Posts Promising EscharEx Data For Chronic Wounds
MediWound Ltd (NASDAQ: MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers (VLUs). 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.